Jean Jacques Bienaime - 13 Jan 2023 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
Chief Executive Officer, Director
Signature
/s/ Laura Randall Woodhead, Attorney-in-Fact
Issuer symbol
BMRN
Transactions as of
13 Jan 2023
Net transactions value
-$881,800
Form type
4
Filing time
18 Jan 2023, 20:41:30 UTC
Previous filing
13 Feb 2023
Next filing
14 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Options Exercise $678,100 +10,000 +3.1% $67.81 330,424 13 Jan 2023 Direct F1
transaction BMRN Common Stock Sale $1,122,500 -10,000 -3% $112.25 320,424 13 Jan 2023 Direct F1, F2
transaction BMRN Common Stock Options Exercise $678,100 +10,000 +3.1% $67.81 330,424 17 Jan 2023 Direct F3
transaction BMRN Common Stock Sale $1,115,500 -10,000 -3% $111.55 320,424 17 Jan 2023 Direct F3
holding BMRN Common Stock 247,533 13 Jan 2023 Shares held by Jean-Jacques Bienaime Family Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to buy Common Stock) Options Exercise $0 -10,000 -4.7% $0.000000 203,130 13 Jan 2023 Common Stock 10,000 $67.81 Direct F1, F4
transaction BMRN Stock Option (Right to buy Common Stock) Options Exercise $0 -10,000 -4.9% $0.000000 193,130 17 Jan 2023 Common Stock 10,000 $67.81 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Trade made pursuant to a 10b5-1 plan executed on November 17, 2022.
F2 The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 100 shares, with the reporting person's purchase of shares at a price of $86.1178 on November 2, 2022. The reporting person has agreed to pay to the Issuer the full amount of the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs.
F3 Trade made pursuant to a 10b5-1 plan executed on May 3, 2022.
F4 Reflects the number of options outstanding after the transactions from this specific stock option grant.